ストックスクリーナーアプリを入手
10.91
0.37%
-0.04
前日終値:
$10.95
開ける：
$10.98
24時間の取引高:
4.91M
Relative Volume:
0.92
時価総額：
$972.55M
収益：
$20.65M
当期純損益:
$-192.65M
株価収益率:
-4.2124
EPS:
-2.59
ネットキャッシュフロー:
$-134.39M
1週間 パフォーマンス:
-1.09%
1か月 パフォーマンス:
-1.89%
6か月 パフォーマンス:
+77.69%
1年 パフォーマンス:
+59.97%
1日の値動き範囲:
$10.90
$10.99
1週間の範囲:
$10.90
$11.09
52週間の値動き範囲:
$2.8647
$11.40
Verve Therapeutics Inc Stock (VERV) Company Profile
VERV を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VERV
Verve Therapeutics Inc
|
10.91 | 985.11M | 20.65M | -192.65M | -134.39M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Verve Therapeutics Inc Stock (VERV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-15 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2024-04-08 | 開始されました | H.C. Wainwright | Buy |
| 2023-04-13 | 開始されました | Canaccord Genuity | Buy |
| 2023-02-01 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-12-15 | 開始されました | Goldman | Sell |
| 2022-10-06 | 開始されました | Credit Suisse | Neutral |
| 2022-08-25 | アップグレード | Stifel | Hold → Buy |
| 2022-06-17 | 開始されました | BMO Capital Markets | Outperform |
| 2022-02-18 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-09-24 | 開始されました | Stifel | Hold |
| 2021-07-12 | 開始されました | Guggenheim | Buy |
| 2021-07-12 | 開始されました | JP Morgan | Neutral |
| 2021-07-12 | 開始されました | Jefferies | Buy |
| 2021-07-12 | 開始されました | William Blair | Outperform |
すべてを表示
Verve Therapeutics Inc (VERV) 最新ニュース
What drives Verve Therapeutics Inc. stock priceExponentially increasing returns - Jammu Links News
What analysts say about Verve Therapeutics Inc. stockHigh-impact investment strategies - Jammu Links News
Is Verve Therapeutics Inc. a good long term investmentFree Market Dynamics Reports - Jammu Links News
Verve Therapeutics Inc. Stock Analysis and ForecastAccelerated profit realization - Jammu Links News
Verve Offers $416K Award To GC Amid Lilly Acquisition - Law360
Verve Therapeutics grants retention bonuses to CFO and COO amid pending acquisition - Investing.com Canada
Verve Therapeutics grants retention bonuses to CFO and COO amid pending acquisition By Investing.com - Investing.com South Africa
Verve Therapeutics Announces Retention Bonus Program for Executives - TipRanks
Why Verve Therapeutics Inc. stock attracts strong analyst attentionDaily Trade Opportunity - beatles.ru
Verve Therapeutics, Inc. (VERV): A Bull Case Theory - MSN
Prime Medicine soars as Jones sees it as an acquisition target - Seeking Alpha
Eli Lilly to acquire gene-editing biotech company Verve Therapeutics for $1.3 billion. Here's why - MSN
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BMO Capital Downgrades Verve Therapeutics to Market Perform, $13.50 Price Target - MarketScreener
Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly - MSN
Lilly To Acquire Verve For One-Time Cardiovascular Treatments - Insider Monkey
Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week - AOL.com
$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Verve Therapeutics, Inc. (NASDAQ: VERV) - TradingView
What is the Intent Behind Eli Lilly's Recent M&A Deals Spree? - Yahoo Finance
VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc.VERV - Business Wire
Verve Therapeutics Stock Price, Quotes and Forecasts - Benzinga
Eli Lilly Acquires Verve Therapeutics In $1.3 Billion Deal - Finimize
Eli Lilly (LLY) Moves to Acquire Verve Therapeutics in $1B Deal - GuruFocus
Lilly to acquire Verve Therapeutics for $1.3 billion - C&EN
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst - Benzinga
Verve Therapeutics’ SWOT analysis: gene-editing stock shows promise amid challenges - Investing.com
Eli Lilly (LLY) Enters Gene-Editing Space with Verve Therapeutics Acquisition - TipRanks
Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports - MSN
Verve Therapeutics downgraded to Hold from Buy at Canaccord - Yahoo Finance
Eli Lilly nears $1.3B deal for Verve Therapeuticsreport - MSN
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement - TradingView
Beyond Obesity: Eli Lilly’s Genetic Medicine Bet On Verve Therapeutics - Forbes
This Verve Therapeutics Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday - Benzinga
HC Wainwright Downgrades Verve Therapeutics (VERV) Rating to Neutral | VERV Stock News - GuruFocus
Jefferies Downgrades Verve Therapeutics (VERV), Lowers Price Tar - GuruFocus
Verve Therapeutics (VERV): Downgrade and Updated Price Target | - GuruFocus
Lilly to acquire Verve Therapeutics to advance gene editing treatments - World Pharmaceutical Frontiers
Lock In The 81.5% Run: Initiating Verve With A Sell (NASDAQ:VERV) - Seeking Alpha
Canaccord Genuity Downgrades Verve Therapeutics to Hold From Buy - marketscreener.com
HC Wainwright Downgrades Verve Therapeutics to Neutral From Buy, $25 Price Target - MarketScreener
Verve Therapeutics downgraded to Neutral from Buy at H.C. Wainwright - TipRanks
Hold Rating on Verve Therapeutics Acquisition by Eli Lilly: Fair Valuation with Low Competing Bid Potential - TipRanks
Verve Therapeutics (VERV) Downgraded After Acquisition Agreement | VERV Stock News - GuruFocus
Lilly Eyes Future of One-Time Cardiovascular Health with $1.3B Verve Therapeutics Acquisition - geneonline.com
Verve Therapeutics downgraded to Hold from Buy at Jefferies - TipRanks
Jefferies cuts Verve Therapeutics stock rating on Lilly acquisition news - Investing.com
M&A News: Verve Therapeutics Stock (VERV) Rallies 75% on News of Potential Acquisition by Eli Lilly - The Globe and Mail
Eli Lilly to acquire for Verve Therapeutics for up to $1.3B - MSN
Verve Therapeutics (VERV) Downgraded Following Acquisition Annou - GuruFocus
Wall Street Analysts See a 367.86% Upside in Verve Therapeutics (VERV): Can the Stock Really Move This High? - MSN
Eli Lilly Bets Big On Gene Editing With Verve Deal - Finimize
Verve Therapeutics Inc (VERV) 財務データ
収益
当期純利益
現金流量
EPS
0.59%
0.34%
大文字化:
|
ボリューム (24 時間):